Targets › HPX
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Oct 2027.
Binds heme and transports it to the liver for breakdown and iron recovery, after which the free hemopexin returns to the circulation. (UniProt, P02790)
Open in Phaseline: the race on HPX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CSL Behring | CSL889 Human hemopexin | HPX | Phase 2 | Sickle Cell Disease Vaso-occlusive Crisis | Oct 2027 |
Sickle Cell Disease Vaso-occlusive Crisis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.